Purpose The antiepidermal growth factor receptor antibody cetuximab shows activity in
irinotecanrefractory metastatic colorectal cancer (mCRC), mainly in wild-type KRAS tumors …

Simple Summary HER2-low breast cancer is an emerging subtype for which very few data
are available, especially within the triple-negative breast cancer (TNBC) group. Our aim was …

Sporadic or hereditary colorectal cancer (CRC) with microsatellite instability (MSI) is
frequently characterized by inflammatory lymphocytic infiltration and tends to be associated …

Background Triple-negative breast cancer (TNBC) treatment is currently restricted to
chemotherapy. Hence, tumor-specific molecular targets and/or alternative therapeutic …

Abstract γδ T cells contribute to the immune response against many cancers, notably
through their powerful effector functions that lead to the elimination of tumor cells and the …

γδ T-cells contribute to the immune response against many tumor types through their direct
cytolytic functions and their capacity to recruit and regulate the biological functions of other …

Background Tumor resistance is a frequent cause of therapy failure and remains a major
challenge for the long-term management of colorectal cancer (CRC). The aim of this study …

In a previous phase II study (THERAPY), cetuximab and trastuzumab combination, as
second‐line after progression with gemcitabine, showed disease stabilization in 27% of 33 …

Simple Summary Tumor microenvironment is critical for cancer progression. The role of the
chemokine receptors in breast cancers is still under investigation. The aim of this study was …

The aberrant hypermethylation of BRCA1 promoter CpG islands induces the decreased
expression of BRCA1 (Breast Cancer 1) protein. It can be detected in sporadic breast cancer …